Dr. Shreyaskumar R. Patel
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 43
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 127
Licensed in Texas since 1990, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
TX license H8791 (first issued 1990; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Physicians Referral Service (2,765 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 127
- Services billed
- 278
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 180 | 89 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 46 | 14 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 30 | 13 |
| New patient office or other outpatient visit, 60-74 minutes | 24 | 24 |
| Hospital discharge day management, more than 30 minutes | 18 | 17 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 15 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Imatinib Mesylate | 31 |
| Stivarga (regorafenib) | 17 |
| Loperamide (loperamide hcl) Other prescribers in Houston, TX | 15 |
| Sunitinib Malate | 14 |
| Ondansetron Hcl Other prescribers in Houston, TX | 13 |
| Daptomycin | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 20 payments worth $23,061 in total to this clinician.
| Daiichi Sankyo Inc. | $13,287 |
|---|---|
| EMD Serono Research & Development Institute, Inc. | $5,857 |
| Merck Kgaa | $3,195 |
| Deciphera Pharmaceuticals Inc. | $600 |
| Gilead Sciences, Inc. | $122 |
| Consulting Fee | $17,332 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $3,790 |
| Travel and Lodging | $1,301 |
| Food and Beverage | $638 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Daiichi Sankyo Inc. Apr 2, 2025 | Consulting Fee Turalio · ONCOLOGY | $6,750 |
| EMD Serono Research & Development Institute, Inc. Jun 17, 2025 | Consulting FeeCompany’s descriptionAdvisory Board Participation (Fee For Service) | $5,857 |
| Merck Kgaa Oct 28, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaking Services (Fee For Service) | $3,195 |
| Daiichi Sankyo Inc. Apr 30, 2025 | Consulting Fee Turalio · ONCOLOGY | $2,700 |
| Daiichi Sankyo Inc. Dec 3, 2025 | Consulting Fee Turalio · ONCOLOGY | $2,025 |
| Deciphera Pharmaceuticals Inc. Dec 9, 2025 | Compensation for services other than consulting (speaking, faculty) QINLOCK · ONCOLOGY | $595 |
| Daiichi Sankyo Inc. Mar 28, 2025 | Travel and Lodging Turalio · ONCOLOGY · travel to MIAMI, FL · in-kind | $448 |
| Daiichi Sankyo Inc. Mar 28, 2025 | Travel and Lodging Turalio · ONCOLOGY · travel to MIAMI, FL · in-kind | $372 |
| Daiichi Sankyo Inc. Mar 28, 2025 | Travel and Lodging Turalio · ONCOLOGY · travel to MIAMI, FL · in-kind | $249 |
| Daiichi Sankyo Inc. Apr 16, 2025 | Travel and Lodging Turalio · ONCOLOGY · travel to CORAL GABLES, FL · in-kind | $88.10 |
All 12 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Deciphera Pharmaceuticals Inc. Dec 9, 2025 | Compensation for services other than consulting (speaking, faculty) QINLOCK · ONCOLOGY | $595 |
| Daiichi Sankyo Inc. Dec 3, 2025 | Consulting Fee Turalio · ONCOLOGY | $2,025 |
| Merck Kgaa Oct 28, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaking Services (Fee For Service) | $3,195 |
| EMD Serono Research & Development Institute, Inc. Jun 17, 2025 | Consulting FeeCompany’s descriptionAdvisory Board Participation (Fee For Service) | $5,857 |
| Daiichi Sankyo Inc. Apr 30, 2025 | Consulting Fee Turalio · ONCOLOGY | $2,700 |
| Daiichi Sankyo Inc. Apr 16, 2025 | Travel and Lodging Turalio · ONCOLOGY · travel to CORAL GABLES, FL · in-kind | $88.10 |
| Daiichi Sankyo Inc. Apr 16, 2025 | Travel and Lodging Turalio · ONCOLOGY · travel to CORAL GABLES, FL · in-kind | $68.91 |
| Daiichi Sankyo Inc. Apr 2, 2025 | Consulting Fee Turalio · ONCOLOGY | $6,750 |
| Daiichi Sankyo Inc. Mar 28, 2025 | Travel and Lodging Turalio · ONCOLOGY · travel to MIAMI, FL · in-kind | $448 |
| Daiichi Sankyo Inc. Mar 28, 2025 | Travel and Lodging Turalio · ONCOLOGY · travel to MIAMI, FL · in-kind | $372 |
| Daiichi Sankyo Inc. Mar 28, 2025 | Travel and Lodging Turalio · ONCOLOGY · travel to MIAMI, FL · in-kind | $249 |
| Daiichi Sankyo Inc. Mar 28, 2025 | Travel and Lodging Turalio · ONCOLOGY · travel to MIAMI, FL · in-kind | $75.38 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $66,604 in research payments for these studies, mostly to the institutions running them.
- A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)
Ptc Therapeutics, Inc. · Terminated · NCT05269355
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.